Drug Information Association Logo

Combination Products and Convergence: An Overview of Clinical Benefits, Regulatory Issues & Manufacturing Challenges

| Online

« Back to Listing


Continuing Education credit or Certificate Program units are not available for Archived Webinars

An estimated 30 percent of all new healthcare products under development today are combination products. Why? Because drugs, biologics and medical devices, when used alone, can only slow or stop the progression of disease or injury. In order to tackle the clinical problems of the future, these products will be combined (called combination products) to treat a wide range of diseases from heart attack and stroke to Alzheimer’s, cancer, diabetes and beyond! In fact, every area of medicine will benefit because we can potentially erase the damage of disease or injury not just stop it – that’s not the next evolutionary advance in medicine, that’s a revolutionary advance, a change in the ethos of how why approach medical problems.

Today, the best known example of a combination product is the drug-eluting stent. Other examples include companion diagnostics and antibody-drug conjugates but that’s just the beginning. What about delivering multiple drugs and biologics on a single device? And what if we apply these drugs and biologics to the device at the patient’s bedside based on that particular patient, i.e., personalized medicine? Or we use one combination product to deliver another combination product? In fact, the true scope of combination products is even broader and includes the emerging areas of therapeutic foods and consumer products as well. The possibilities are endless and the best is yet to come! The quintessential example of a combination product is what we are now doing in tissue engineering (a.k.a. regenerative medicine) and biomedical nanotechnology. During this webinar, participants will be exposed to a wide range of examples of combination products on the market, under development and on the drawing board.

This archived webinar will be available for purchase through December 31, 2014.

Who Should Attend 

This webinar is designed for:

  • Drug Development and R&D Professionals
  • Pharmaceutical and Medical device and Diagnostics Professionals
  • Regulatory, Clinical and Other Professionals Responsible for Developing Drug/Device Combinations and Companion Diagnostics
  • Regulatory Affairs Professionals

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Define combination products
  • Identify examples of combination products on the market, under development and on the drawing board

Contact Information 

Registration Questions
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100
Fax: +1.215.442.6199

Questions on Archived Webinar
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199

Technical Requirements 

Click here for minimum system requirements.


Previous Next

Registration Fees 

Other Fees

Group Site
Group Plus


Member Government Individual
Member Academia Individual
Member Individual


NonMember Government Individual
NonMember Academia
NonMember Individual
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.

No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top